Tirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist developed for type 2 diabetes management. It integrates the actions of both incretins into a single molecule, offering once-weekly dosing for effective blood sugar control and weight management.
Description
Product Introduction
Tirzepatide was developed as a dual agonist to both GLP-1 and gastric inhibitory polypeptide (GIP) receptors. Similar to GLP-1, GIP is an incretin hormone that functions to induce insulin secretion. Tirzepatide is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems.
Tirzepatide is a once-weekly GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist that integrates the actions of both incretins into a single novel molecule.
Product Description
- Application Field
- Type 2 diabetes treatment, weight management, metabolic syndrome, peptide drug API
- Packaging
- Custom packaging per client requirements
- Storage Conditions
- -20°C, protected from light, sealed storage
- Shelf Life
- 2 years
Specifications
| Appearance | White to off-white powder |
| Purity (HPLC) | ≥98% |
| Peptide Content | ≥80% |
